Type IV (Cell-Mediated or Delayed) Hypersensitivity
Type IV hypersensitivity, also known as cell-mediated or delayed-type hypersensitivity (DTH), is the unique category of exaggerated immune response that is orchestrated by T lymphocytes rather than by antibodies, which mediate the immediate Types I, II, and III reactions. Unlike the immediate types, a Type IV reaction takes a significant amount of time to manifest, typically developing 24 to 72 hours following the initial contact with the antigen, hence the term ‘delayed.’
This reaction is critical for protective immunity against intracellular pathogens such as viruses, fungi, and certain bacteria (like *Mycobacterium tuberculosis*), but it is also the mechanism underlying various pathological conditions, including certain drug reactions, autoimmune diseases, and allergic responses to environmental substances. The entire process hinges on the adaptive immune system’s memory and the destructive power of T cells and activated macrophages.
The Two-Phase Mechanism: Sensitization
The Type IV reaction is accomplished in two distinct stages: the sensitization phase and the elicitation (or effector) phase. The sensitization phase is the initial contact with the antigen and occurs without observable symptoms. It begins when an antigen, such as an environmental chemical (a hapten), a protein from an intracellular microbe, or a host cell auto-antigen, is captured and processed by an Antigen-Presenting Cell (APC), typically a macrophage or a dendritic cell.
The APC then travels to a nearby lymph node, where it presents the processed antigen fragments in complex with Major Histocompatibility Complex (MHC) molecules—MHC Class II for CD4+ T cells, and potentially MHC Class I for CD8+ T cells. This presentation activates and primes the specific, naïve CD4+ T helper (Th) cells, which proliferate and differentiate into memory T cells, primarily the Th1 and Th17 subsets. This initial exposure effectively ‘sensitizes’ the immune system, establishing the foundation for a rapid and intense response upon any future encounter with the same antigen.
The Elicitation Phase: T-Cell and Cytokine Cascade
The elicitation phase is the clinically visible part of the reaction. It occurs upon secondary (or repeated) exposure to the antigen. When the sensitized T cells re-encounter the antigen at the site of exposure, they rapidly respond. The two main subsets of T cells mediate the inflammatory damage:
Firstly, the CD4+ T helper cells (specifically Th1 and Th17) release an array of inflammatory mediators known as cytokines. Key among these are Interleukin-2 (IL-2), which promotes T-cell proliferation, and Interferon-gamma (IFN-gamma). IFN-gamma is a potent activator of macrophages, transforming them into hyper-activated cells capable of increased phagocytosis and the production of hydrolytic enzymes and nitric oxide radicals. The sustained recruitment of monocytes and their subsequent differentiation into activated macrophages and epithelioid cells is the central event that causes the characteristic tissue destruction and localized swelling (induration).
Secondly, CD8+ cytotoxic T cells become activated. Their role is to directly recognize and destroy target cells that display the antigen on their surface, such as virally infected cells or, pathologically, host cells in the case of autoimmune or drug reactions. The combined action of cytokine-induced inflammation from CD4+ cells and direct cytotoxicity from CD8+ cells leads to the eventual tissue damage seen in Type IV hypersensitivity.
Examples of Type IV Hypersensitivity: Allergic Contact Dermatitis
Allergic Contact Dermatitis (ACD) is one of the most common and classic examples of Type IV hypersensitivity, often seen in response to small, lipid-soluble molecules that act as haptens. These include chemicals found in poison ivy and poison oak (urushiol), metals like nickel, and certain topical medications. These haptens penetrate the skin and covalently bind to carrier proteins, forming a complex that is then picked up by skin-resident APCs (Langerhans cells/dendritic cells).
Upon re-exposure, the sensitized T cells are activated in the skin, leading to the characteristic skin changes—erythema, itching, vesication, and eczema—that develop hours to days after contact. The inflammatory response is essentially an epidermal necrosis caused by the massive infiltration of T cells and macrophages, mediated by the release of pro-inflammatory cytokines.
Examples of Type IV Hypersensitivity: Tuberculin Reaction and Granuloma Formation
The Tuberculin skin test (Mantoux test), used to screen for prior exposure to *Mycobacterium tuberculosis* (TB), is the archetypal example of tuberculin-type DTH. A purified protein derivative (PPD) from the bacteria is injected intradermally. A positive result, indicated by induration (a firm, palpable swelling) and erythema developing at the site 48-72 hours later, signifies that the individual has previously been sensitized to the TB antigens and has memory T cells ready to launch a response.
A more severe, chronic manifestation of DTH is the formation of a granuloma. This occurs when the immune system cannot completely eliminate a persistent intracellular pathogen or non-degradable foreign material. The chronic stimulation of T cells leads to a sustained release of IFN-gamma, which continuously recruits and hyper-activates macrophages. These activated macrophages eventually transform into epithelioid cells, which, along with multinucleated giant cells, attempt to wall off the infected tissue in a protective, yet often destructive, lesion known as a granuloma. Granulomatous hypersensitivity is also seen in chronic infectious diseases like leprosy and non-infectious conditions like sarcoidosis.
Examples of Type IV Hypersensitivity: Autoimmune Diseases and Transplant Rejection
Type IV hypersensitivity is also implicated in a range of significant human diseases, particularly autoimmune disorders and tissue rejection. In **Type 1 Diabetes Mellitus**, CD8+ cytotoxic T cells mistakenly recognize and destroy the insulin-producing pancreatic beta cells, which are seen as foreign. Similarly, in **Multiple Sclerosis (MS)**, T cells target and destroy the myelin sheath antigens surrounding nerve fibers, leading to neurological damage and paralysis. **Hashimoto’s thyroiditis** and **Inflammatory Bowel Disease** also involve T-cell mediated tissue damage.
Furthermore, **Acute and Chronic Transplant Rejection** are largely cell-mediated responses. In these scenarios, the recipient’s T cells (both CD4+ and CD8+) recognize the donor organ’s Major Histocompatibility Complex (MHC) molecules as foreign antigens, leading to an inflammatory attack on the graft tissue that ultimately causes its rejection. Other examples include severe cutaneous drug reactions like **Stevens-Johnson Syndrome (SJS)** and **Toxic Epidermal Necrolysis (TEN)**, where drug-specific cytotoxic T cells mediate widespread tissue necrosis.
Conclusion
In summary, Type IV hypersensitivity reactions, while serving a protective function against intracellular threats, represent a double-edged sword. Their delayed, T-cell and macrophage-driven mechanism is responsible for vital immune surveillance, but when misdirected against innocuous environmental antigens, pharmaceutical agents, or self-antigens, they become the direct cause of chronic tissue damage and debilitating inflammatory diseases. Understanding this mechanism is vital for diagnosing and treating the diverse pathologies associated with this unique class of immune over-reaction.